Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases

---

Copy For Citation

GOOSSENS H., MALHOTRA-KUMAR S., ERAKSOY H., Unal S., grabein b., MASTERTON R., ...More

CLINICAL MICROBIOLOGY AND INFECTION, vol.10, no.8, pp.760-762, 2004 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 10 Issue: 8
• Publication Date: 2004
• Doi Number: 10.1111/j.1469-0691.2004.00957.x
• Journal Name: CLINICAL MICROBIOLOGY AND INFECTION
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.760-762
• Hacettepe University Affiliated: Yes

Abstract

An omnibus survey of microbiologists (n = 400) and a survey of participants (n = 49) in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme were conducted to determine the awareness and prevalence of extended-spectrum beta-lactamases (ESBLs), and the regularity and method of screening. Of the omnibus survey participants, 69% screened regularly for ESBLs, compared with 83% of MYSTIC participants. In both surveys, ESBLs were more common in Klebsiella pneumoniae (73% and 79%, respectively) and Escherichia coli (63% and 81%, respectively) than in other bacteria. The surveys demonstrated that awareness of, and testing for, ESBLs is inconsistent.